Abstract
Low-dose blonanserin was effective for treating severe delusions in six patients with various types of dementia, and it was also well tolerated. Delusion and hallucination scores, as measured by the Neuropsychiatric Inventory, improved, and extrapyramidal symptom scores, as measured by the Drug-Induced Extrapyramidal Symptoms Scale, were unchanged. Blonanserin has strong dopamine D2 receptor-, 5-hydroxytryptamine 2A receptor-, and dopamine D3 receptor-blocking activities and weak 5-hydroxytryptamine-2C, α1-, histamine H1-, and muscarinic M1-blocking activities. Its unique characteristics may make it suitable for treating severe delusions and hallucination in patients with dementia. Psychogeriatrics
Original language | English |
---|---|
Pages (from-to) | 144-146 |
Number of pages | 3 |
Journal | Psychogeriatrics |
Volume | 15 |
Issue number | 2 |
DOIs | |
Publication status | Published - Jun 1 2015 |
Keywords
- Blonanserin
- D receptor
- Delusion
- Dementia
- Hallucination
ASJC Scopus subject areas
- Gerontology
- Geriatrics and Gerontology
- Psychiatry and Mental health